Liver/Biliary Disorders News

Over recent years, there has been increased interest and attention to hepatitis delta virus, as we are beginning to understand that this is a real problem that at the moment is under-addressed and under-identified.

Despite being the smallest virus capable of causing human disease, it is estimated that up to 80% of patients with hepatitis delta virus will progress to liver cirrhosis and more than 50% will die of liver disease within 10 years of diagnosis.

Neoadjuvant immunotherapy may allow more people with hepatocellular carcinoma to undergo surgical resection, according to retrospective study results.

A model using both clinical and imaging data predicted the absence of high-risk varices in patients with unresectable hepatocellular carcinoma and may help avoid unnecessary upper endoscopy in low-risk patients, research showed.

Gilead’s Livdelzi, a selective peroxisome proliferator-activated receptor delta agonist, has received accelerated FDA approval for the treatment of primary biliary cholangitis, according to a company release.

A hepatitis C elimination program in Georgia reduced the estimated annual incidence of new infections by 61% since its launch in April 2015, which may accelerate efforts to reach the global 2030 elimination goal.

With the FDA label for Rezdiffra excluding the need for liver biopsy, experts proposed recommendations to “fill the gap” on how to leverage noninvasive tests to assess treatment response in metabolic dysfunction-associated steatohepatitis.

Researchers estimated that nearly 15.6 million Americans consumed at least one potentially hepatotoxic botanical product in the past 30 days, similar to usage reports for simvastatin and NSAIDS.

Patients who underwent liver transplantation vs. alternative therapy for unresectable colorectal liver metastasis had higher progression-free and overall survival, as well as lower rates of recurrence, researchers reported in JAMA Surgery.

Pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, lowered liver fat content, markers of inflammation and body weight in patients with metabolic dysfunction-associated steatotic liver disease and obesity, research showed.